DOCSLIB.ORG

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin Or Insulin Lispro in Subjects with Type 1 Diabetes a Dose-Timing Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin Or Insulin Lispro in Subjects with Type 1 Diabetes a Dose-Timing Study Emerging Treatments and Technologies ORIGINAL ARTICLE Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes A dose-timing study 1 3 CHRISTIAN WEYER, MD MARIA GUTIERREZ, MD espite important advances in the 1 1 ALAN GOTTLIEB, PA YAN WANG, PHD delivery and pharmacology of insu- 1 1 DENNIS D. KIM, MD JAMES A. RUGGLES, PHD 1 1 lin (1,2), most patients with type 1 AREN UTZ PHD RVILLE OLTERMAN MD D K L , O G. K , 2 1 diabetes are still unable to achieve glyce- SHERWYN SCHWARTZ, MD DAVID G. MAGGS, MD mic targets with insulin therapy alone (3,4). The limitations of current insulin replacement therapy are especially evi- dent during the postprandial period, when rapid and profound changes in glu- OBJECTIVE — To assess the postprandial glucose-lowering effect of the human amylin an- alog pramlintide when given with either regular insulin or insulin lispro in subjects with type 1 cose flux are required to accommodate diabetes, with an emphasis on the optimal dose timing relative to meals. the sudden appearance of meal-derived glucose into the circulation (5–7). RESEARCH DESIGN AND METHODS — In this randomized, single-blind, placebo- In healthy individuals, meal ingestion controlled, five-way crossover study, 19 subjects with type 1 diabetes using regular insulin and leads to the rapid release of two gluco- 21 subjects with type 1 diabetes using insulin lispro underwent five consecutive mixed meal regulatory ␤-cell hormones, insulin and tests. In randomized order, subjects received subcutaneous injections of placebo at Ϫ15 min or amylin (8). These hormones act in con- 60 ␮g pramlintide at Ϫ15, 0, ϩ15, or ϩ30 min relative to the meal after an overnight fast. cert to limit the postprandial glucose ex- Ϫ Regular insulin or insulin lispro was injected at 30 and 0 min, respectively, at doses that were cursion, with amylin reducing the rate of adjusted appropriately for both the content of the standardized meal and the anticipated effects glucose appearance into the circulation of pramlintide. Plasma glucose concentrations were measured before and during the 4-h post- meal period. and insulin stimulating the rate of glucose disappearance from the circulation (5–7). RESULTS — In both the regular insulin and insulin lispro groups, pramlintide injections at all In addition, the secretion of glucagon, the four time points lowered the postprandial glucose excursion (36 to Ͼ100% reduction in incre- main hormonal stimulus for hepatic glu- mental area under the concentration time curve from 0 to 4 h (AUC0–4 h) compared with cose production, is normally suppressed placebo. However, only preprandial injections of pramlintide (Ϫ15 and 0 min) were able to in response to a carbohydrate meal (9). prevent the initial postprandial surge in glucose. The optimal time for pramlintide injection was In people with type 1 diabetes, post- 0 min, which reduced the postprandial glucose excursion by Ͼ100% compared with regular prandial insulin and amylin responses are Ϫ Ϯ Ϯ ⅐ Ϫ1 ⅐ Ϫ1 Ͻ insulin plus placebo (incremental AUC0–4 h: 0.6 2.5 vs. 11.0 2.9 mmol h l , P Ϯ completely absent (5–8), and glucagon se- 0.0007) and by 75% compared with insulin lispro plus placebo (incremental AUC0–4 h: 2.5 Ϫ Ϫ cretion is abnormally increased, leading to 2.1 vs. 10.0 Ϯ 2.5 mmol ⅐ h 1 ⅐ l 1, P Ͻ 0.0098). No serious adverse events were reported. excessive postprandial glucose excursions CONCLUSIONS — Pramlintide, given at or just before a meal, reduces the postprandial (9–11). Mealtime insulin replacement re- glucose excursion in subjects with type 1 diabetes, regardless of whether added to regular insulin duces postprandial hyperglycemia (12). or a rapid-acting insulin analog. However, even with the use of rapid-acting insulin analogs, it is still not possible to rep- Diabetes Care 26:3074–3079, 2003 licate the rapid release of endogenous insu- lin into the portal vein or to correct the ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● abnormal postprandial rise in glucagon of- From the 1Amylin Pharmaceuticals, Inc., San Diego, California; the 2Diabetes and Glandular Disease Re- ten seen in patients with type 1 diabetes search Associates, San Antonio, Texas; and the 3Clinical Studies, Ltd., Fort Lauderdale, Florida. (6,7). Both of these abnormalities contrib- Address correspondence and reprint requests to Christian Weyer, MD, Amylin Pharmaceuticals, Inc., ute to the lack of appropriate suppression of 9360 Towne Centre Dr., San Diego, CA 92121. E-mail: [email protected]. Received for publication 2 April 2003 and accepted in revised form 24 July 2003. hepatic glucose production and, hence, to C.W., A.G., D.D.K., K.L., S.S., Y.W., J.A.R., O.G.K., and D.G.M. are employed by and hold stock in excessive postprandial glucose excursions Amylin Pharmaceuticals, Inc. S.S. is a member of an advisory panel for Amylin Pharmaceuticals, Inc. J.A.R. (9–11). also holds stock in Bristol-Myers Squibb and Schering Plough. Pramlintide is a synthetic analog of Abbreviations: AUC, area under the curve. A table elsewhere in this issue shows conventional and Syste`me International (SI) units and conversion human amylin that is under development factors for many substances. as an adjunct to insulin therapy in people © 2003 by the American Diabetes Association. with types 1 and 2 diabetes (5–7,13). 3074 DIABETES CARE, VOLUME 26, NUMBER 11, NOVEMBER 2003 Weyer and Associates Short-term clinical studies in patients and all subjects provided written in- reduction to avoid postprandial hypogly- with type 1 diabetes have shown that formed consent before participation. This cemia if the premeal glucose was near- mealtime amylin replacement via pre- study was conducted in accordance with normal) but not for the purpose of prandial injections of pramlintide, in ad- principles described in the Declaration of glycemic control (dose increase to im- dition to regular insulin injections, Helsinki (1964), including all amend- prove postprandial hyperglycemia). The corrects postprandial hyperglucagonemia ments up to and including the South Af- basal insulin regimens, which were com- (14) and slows the rate of gastric empty- rica revision (1996). prised of continuous subcutaneous insu- ing (15,16). As a result, the appearance of lin infusion (n ϭ 8) or subcutaneous both endogenous (liver-derived) and ex- Study design injections of intermediate- or long-acting ogenous (meal-derived) glucose into the Within 14 days after screening, consenting insulin (n ϭ 32), were held constant circulation is controlled to better match subjects were admitted to the clinical re- throughout the study. the rate of insulin-mediated glucose dis- search center for at least 6 days. Between appearance, leading to a substantial re- screening and admission, subjects were Statistical analyses duction of postprandial glucose asked to record their daily food intake, in- Main pharmacodynamic parameters in- excursions (17–19). Long-term clinical sulin regimen, and self-monitored blood cluded the incremental plasma glucose studies have shown that the postprandial glucose results in a diary. Upon admission, area under the concentration time curve glucose lowering effect of pramlintide each subject underwent a mixed meal test (AUC) from 0 to 2 h (AUC0–2h), incre- translates into a clinically meaningful and on 5 consecutive days in a randomized, sin- mental AUC0–4h, and the incremental statistically significant reduction in A1C gle-blind, placebo-controlled, five-way plasma glucose concentrations at specific in patients with types 1 and 2 diabetes crossover design. The meal was a standard- sampling times. The mean Ϯ SEM incre- (20–23). ized breakfast, consisting of a bagel with mental plasma glucose concentration The objective of the present study was margarine and jam, cheese, yogurt, milk, profiles were calculated and plotted by to further characterize the effect of pram- and orange juice. The size of the meal was treatment and by study group. For each lintide on postprandial glucose concen- calculated individually to provide 30% of a study group, the pharmacodynamic pa- trations when used as an adjunct to either subject’s total daily caloric requirements rameter data were summarized descrip- regular insulin or insulin lispro, with an with a macronutrient composition accord- tively and were analyzed using mixed emphasis on the optimal dose timing rel- ing to the American Diabetes Association effect models. The mixed effect models ative to meals. nutritional recommendations (55%/15%/ included treatment, treatment sequence, 30% of kcal from carbohydrate/protein/fat, and period as fixed effects and subject- RESEARCH DESIGN AND respectively). The size of the standardized within-sequence as random effects. METHODS breakfast meal was the same on each study The P values for comparisons among day for each individual, and the meal was the least square means of the incremental Study population always consumed within 15 min. AUC0–2h, incremental AUC0–4h, and in- A total of 21 subjects with type 1 diabetes On each day, subjects received one of cremental glucose concentrations at vari- using insulin lispro and 19 subjects with five treatments (a subcutaneous injection of ous time points between dose timings type 1 diabetes using regular insulin un- placebo at Ϫ15minor60␮g pramlintide were provided. Because the study was not derwent a standardized mixed meal test [0.6 mg/ml, Amylin Pharmaceuticals, Inc., powered to perform multiple compari- on 5 consecutive days. Subjects were San Diego, CA] at Ϫ15, 0, ϩ15, or ϩ30 sons, the P values were not adjusted for 18–65 years of age and had the following min relative to the standardized breakfast) multiple comparisons. characteristics: a history of type 1 diabetes according to a randomized sequence, after Safety evaluations were based on re- for at least 1 year, a baseline A1C value of an overnight fast.
Load more

Recommended publications
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
    [Show full text]
  • Combining a Glucagon-Like Peptide-1 Receptor Agonist with Basal Insulin: the Why and How
    Combining a Glucagon-like Peptide-1 Receptor Agonist with Basal Insulin: The Why and How Case Study Mary is a 61 year-old female diagnosed with type 2 diabetes mellitus (T2DM) 8 years ago. She was initially managed with the combination of lifestyle modification and metformin. Since that time she was treated with a sulfonylurea, but it was discontinued due to symptomatic hypoglycemia. She was also treated with pioglitazone, but significant fluid retention led to it discontinuation. A year-and-a- half ago, basal insulin was added to her lifestyle and metformin management. She now administers 52 units (0.62 units/kg) once daily at bedtime. Since starting basal insulin, she has experienced 3 episodes of mild hypoglycemia. Since her diagnosis, Mary’s HbA1c has never been <7.0%; her current HbA1c is 7.9%. Over the past month, her fasting plasma glucose (FPG) has ranged from 103 mg/dL to 136 mg/dL and her postprandial glucose (PPG) from 164 mg/dL to 213 mg/dL. She has gained 2.6 kg since starting basal insulin and her body mass index is now 31 kg/m2. Her blood pressure is 134/82 mmHg. She experiences occasional tingling in her feet. Eye examination reveals grade 1 retinopathy. Current medications are: metformin 1000mg twice daily, basal insulin 52 units once daily at bedtime, and hydrochlorothiazide 25 mg once daily. Her family physician notes that Mary’s FPG is reasonably well-controlled, yet her HbA1c and PPG remain elevated. He is also concerned about her episodes of hypoglycemia and weight gain and the evidence indicating microvascular damage.
    [Show full text]
  • Performance of the Insulin-Only Ilet Bionic Pancreas and The
    e118 Diabetes Care Volume 44, June 2021 Performance of the Insulin-Only Luz E. Castellanos,1 Courtney A. Balliro,1 Jordan S. Sherwood,1 Rabab Jafri,1 iLet Bionic Pancreas and the Mallory A. Hillard,1 Evelyn Greaux,1 Rajendranath Selagamsetty,2 Hui Zheng,3 Bihormonal iLet Using Firas H. El-Khatib,2 Edward R. Damiano,2,4 and Dasiglucagon in Adults With Type Steven J. Russell1 1 Diabetes in a Home-Use Setting Diabetes Care 2021;44:e118–e120 | https://doi.org/10.2337/dc20-1086 Reductions in blood glucose levels in with insulin lispro (Eli Lilly) or aspart (Table 1). The mean CGM glucose and people with diabetes are often achieved (Novo Nordisk), the bihormonal iLet for time in range (70–180 mg/dL) were 149 at the expense of increased hypoglyce- 7dayswithdasiglucagon(4mg/mL) ±13mg/dLand72±8%,respectively,in mia. A novel approach is to automati- and insulin lispro or aspart, or both, us- the insulin-only period, and 139 ± 11 cally deliver microdose glucagon when ing the same glucose target (110 mg/ mg/dL and 79 ± 9%, respectively, in the automation of insulin delivery alone is dL), in random order. There were no re- bihormonal period. The mean daily car- not sufficient to prevent hypoglycemia. strictions on diet or exercise. The prima- bohydrates consumed to prevent or The approach requires a bihormonal de- ry outcomes were prespecified iLet treat hypoglycemia were 16 ± 13 g and vice and a stable form of glucagon or operational thresholds. The key second- 18 ± 21 g in the insulin-only and bihor- glucagon analog.
    [Show full text]
  • (Pram) and Insulin A21G Improves Post-Prandial Glucose Vs Novolog
    ADO09, A Co-Formulation Of Pramlintide (Pram) and Insulin A21G improves Post-Prandial Glucose Vs Novolog® in Type 1 Diabetes (T1DM) G.Meiffren¹, G.Andersen², R.Eloy¹, C.Seroussi¹, C.Mégret¹, S.Famulla², Y.-P Chan¹, M.Gaudier¹, O.Soula¹, J.H. DeVries²,T.Heise² (1 Adocia, Lyon, France ; 2 Profil, Neuss, Germany) Introduction & Background Overall safety Outpatient period results - CGM metrics o ADO09 (M1Pram) is a co-formulation of pramlintide and insulin A21G o Both treatments were well tolerated without any treatment-related serious adverse events o Most of the CGM metrics (TiR [70-180], TiR [80-140], mean blood glucose per day), were significantly improved developed to leverage the beneficial effects of pramlintide on post-prandial (Table 2). As expected M1Pram had numerically more, mostly gastrointestinal adverse events with M1Pram (Table 4). Postprandial and mean 24-hour glucose profiles were improved with M1Pram (Fig. 3) glucose without additional injections than insulin aspart Table 4: CGM metrics, all days. Significant differences are marked in bold Objective and design o No severe hypoglycemia were seen, slightly more hypoglycemic events occurred with M1Pram Ratio of LSMean* o To compare the effect of M1Pram and insulin aspart (Novolog®, Novo than with aspart (Table 3) Difference Parameter Treatment LS Mean M1Pram / Aspart P-value Nordisk) on post-prandial glucose control, glycemic control assessed by Table 2: Incidence of adverse events throughout the trial (M1Pram-Aspart) (95% CI) CGM and safety/tolerability M1Pram Aspart M1Pram
    [Show full text]
  • TRULICITY, INN-Dulaglutide
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Trulicity 0.75 mg solution for injection in pre-filled pen Trulicity 1.5 mg solution for injection in pre-filled pen Trulicity 3 mg solution for injection in pre-filled pen Trulicity 4.5 mg solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Trulicity 0.75 mg solution for injection in pre-filled pen Each pre-filled pen contains 0.75 mg of dulaglutide* in 0.5 ml solution. Trulicity 1.5 mg solution for injection in pre-filled pen Each pre-filled pen contains 1.5 mg of dulaglutide* in 0.5 ml solution. Trulicity 3 mg solution for injection in pre-filled pen Each pre-filled pen contains 3 mg of dulaglutide* in 0.5 ml solution. Trulicity 4.5 mg solution for injection in pre-filled pen Each pre-filled pen contains 4.5 mg of dulaglutide* in 0.5 ml solution. *produced in CHO cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Type 2 Diabetes Mellitus Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.
    [Show full text]
  • Type 2 Diabetes Adult Outpatient Insulin Guidelines
    Diabetes Coalition of California TYPE 2 DIABETES ADULT OUTPATIENT INSULIN GUIDELINES GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes 6,7,8 medications. (Consider insulin as initial therapy if A1C very high, such as > 10.0%) 6,7,8 Start with BASAL INSULIN for most patients 1,6 Consider the following goals ADA A1C Goals: A1C < 7.0 for most patients A1C > 7.0 (consider 7.0-7.9) for higher risk patients 1. History of severe hypoglycemia 2. Multiple co-morbid conditions 3. Long standing diabetes 4. Limited life expectancy 5. Advanced complications or 6. Difficult to control despite use of insulin ADA Glucose Goals*: Fasting and premeal glucose < 130 Peak post-meal glucose (1-2 hours after meal) < 180 Difference between premeal and post-meal glucose < 50 *for higher risk patients individualize glucose goals in order to avoid hypoglycemia BASAL INSULIN Intermediate-acting: NPH Note: NPH insulin has elevated risk of hypoglycemia so use with extra caution6,8,15,17,25,32 Long-acting: Glargine (Lantus®) Detemir (Levemir®) 6,7,8 Basal insulin is best starting insulin choice for most patients (if fasting glucose above goal). 6,7 8 Start one of the intermediate-acting or long-acting insulins listed above. Start insulin at night. When starting basal insulin: Continue secretagogues. Continue metformin. 7,8,20,29 Note: if NPH causes nocturnal hypoglycemia, consider switching NPH to long-acting insulin. 17,25,32 STARTING DOSE: Start dose: 10 units6,7,8,11,12,13,14,16,19,20,21,22,25 Consider using a lower starting dose (such as 0.1 units/kg/day32) especially if 17,19 patient is thin or has a fasting glucose only minimally above goal.
    [Show full text]
  • Safety of Insulin Lispro and a Biosimilar Insulin Lispro When
    DSTXXX10.1177/1932296817753644Journal of Diabetes Science and TechnologyThrasher et al 753644research-article2018 Original Article Journal of Diabetes Science and Technology 2018, Vol. 12(3) 680 –686 Safety of Insulin Lispro and a Biosimilar © 2018 Diabetes Technology Society Insulin Lispro When Administered Reprints and permissions: sagepub.com/journalsPermissions.nav Through an Insulin Pump DOI:https://doi.org/10.1177/1932296817753644 10.1177/1932296817753644 journals.sagepub.com/home/dst James Thrasher, MD1, Howard Surks, MD2, Irene Nowotny, PhD3, Suzanne Pierre, MSc4, Baerbel Rotthaeuser, PhD3, Karin Wernicke-Panten, MD3, and Satish Garg, MD5 Abstract Background: SAR342434 (U100; SAR-Lis; insulin lispro) is a biosimilar/follow-on to insulin lispro (U100; Ly-Lis). Similar pharmacokinetics/pharmacodynamics between the two products has been demonstrated in a hyperinsulinemic euglycemic clamp study. The current study evaluated the safety of SAR-Lis and Ly-Lis when administered by continuous subcutaneous insulin infusion (CSII; insulin pumps). Methods: This was a randomized, open-label, 2 × 4-week, two-arm crossover study in 27 patients with type 1 diabetes mellitus (NCT02603510). The main outcome was the incidence of infusion set occlusions (ISOs), defined as failure to correct hyperglycemia (plasma glucose ≥≥ 300 mg/dl) by 50 mg/dl within 60 minutes by insulin bolus via the pump. Secondary outcomes included intervals between infusion set changes, treatment-emergent adverse events (TEAEs) including infusion site, hypersensitivity reactions and hypoglycemic events, and safety. Results: The number of patients reporting at least one ISO was small: 6/25 patients on SAR-Lis reported 14 ISOs and 4/27 on Ly-Lis reported nine ISOs. The estimated difference in ISO risk for SAR-Lis versus Ly-Lis was 7.9% (95% CI, –1.90 to 17.73).
    [Show full text]
  • Diabetes Recommendations and Tier Coverage Chart
    DIABETES RECOMMENDATIONS AND TIER COVERAGE CHART The American Diabetes Association guidelines for 2020, recommend metformin as the preferred initial treatment for type 2 diabetes (T2DM) along with weight management and physical activity. In patients who have established ASVD or at high risk, CKD, or HF, a SGLT2i or GLP-1 receptor with proven efficacy is recommended independent of A1C. • ASCVD dominates: o GLP-1RA with proven CVD benefit (dulaglutide, liraglutide, injectable semaglutide) OR o SGLT2i with proven CVD benefit (canagliflozin, empagliflozin) if adequate eGFR • HF or CKD dominates: o SGLT2i with evidence of reducing HF and/or CKD progression (empagliflozin, canagliflozin, dapagliflozin) if adequate eGFR OR o If SGLT2i intolerant/contraindicated or eGFR is inadequate, then GLP-1RA with proven CVD benefit In individuals without established cardiovascular disease, pharmacological treatment should be patient-centered taking into account side-effects, cost, impact on weight, risk of hypoglycemia, and other patient preferences. For more detailed information regarding ADA recommendations for pharmacological agents to treat T2DM click here. The following chart is a list of oral and injectable diabetes medications listed by class with their respective A1C reduction and insurance coverage and/or coverage requirements for BCBS, HPHC, Tufts, TMP, and MassHealth. Tufts Medicare Medications BCBSMA HPHC Tufts Preferred MassHealth Biguanides A1C reduction: 1-1.5% metformin Tier 1 Tier 1;2 Tier 1 Tier 1 Covered Glucoghage (metformin) NC NC NC;Tier
    [Show full text]
  • Tresiba-Product-Monograph.Pdf
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION TRESIBA® insulin degludec injection TRESIBA® FlexTouch® 100 U/mL, Solution for injection in a pre-filled pen TRESIBA® FlexTouch® 200 U/mL, Solution for injection in a pre-filled pen Subcutaneous Antidiabetic Agent Long-Acting Basal Insulin Analogue ATC Code: A10AE06 Novo Nordisk Canada Inc. Date of Initial Authorization: AUG 25, 2017 101-2476 Argentia Road Date of Revision: Mississauga, Ontario JUL 23, 2021 Canada L5N 6M1 Submission Control Number: 250276 Product Monograph Master Template Template Date: September 2020 TRESIBA® (insulin degludec injection) Page 1 of 2 RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions 03/2021 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. TABLE OF CONTENTS ..............................................................................................................2 1 INDICATIONS ..................................................................................................................4 1.1 Pediatrics ................................................................................................................4 1.2 Geriatrics ................................................................................................................4 2 CONTRAINDICATIONS ..................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .......................................................4 4 DOSAGE AND ADMINISTRATION
    [Show full text]
  • Prior Authorization Protocol NATL
    Prior Authorization Protocol BYDUREON™ (exenatide extended-release for injectable suspension), BYETTA TM (exenatide), SYMLIN PEN (pramlintide acetate), TANZEUM TM (albiglutide) TRULICITY™ (dulaglutide), VICTOZA ® (liraglutide) NATL Coverage of drugs is first determined by the member`s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document. I. FDA Approved Indications: • Bydureon, Byetta, Tanzeum, Trulicity, Victoza: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus • Symlin: Adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. II. Health Net Approved Indications and Usage Guidelines: Bydureon/ Byetta/Tanzeum/Trulicity/Victoza: • Diagnosis of type 2 diabetes AND • Documentation of baseline A1C AND • Failure or clinically significant adverse effects to at least a 3 month trial of metformin (unless contraindicated) REAUTHORIZATION REQUESTS: If inadequate response to GLP-1 receptor agonist ( i.e. <0.5% reduction in A1c) at the end of initial authorization period, either a switch to insulin therapy, addition of insulin(s) to Victoza or a referral to an endocrinologist will be required. Reauthorization requests require documentation of continued metformin therapy (unless contraindicated). Symlin: • Diagnosis of Diabetes Mellitus Type 1 or 2 AND • Failure to achieve desired blood glucose level despite 3 months of three or more daily mealtime insulin (e.g. Humalog ®, Humulin ® R) injections or use of an insulin pump Confidential & Proprietary Page 1 Draft Prepared: 06.17.05 JP Approved by Health Net Pharmacy & Therapeutics Committee: 11.16.05, 04.06, 5.21.08, 11.19.08, 11.19.09, 8.25.10, 11.9.11, 11.14.12, 11.20.13, 11.19.14, 11.18.15 Updated: 04.07.06.
    [Show full text]
  • A Direct Comparison of Insulin Aspart and Insulin Lispro in Patients with Type 1 Diabetes
    Pathophysiology/Complications ORIGINAL ARTICLE A Direct Comparison of Insulin Aspart and Insulin Lispro in Patients With Type 1 Diabetes 1 1 JOHANNES PLANK, MD BARBARA SEMLITSCH, RN human soluble insulin is performed as 1 1 ANDREA WUTTE, MSC ROMANA SOMMER, MD standard treatment regimen by a majority 1 2 GERNOT BRUNNER, MD SABINE HIRSCHBERGER, MD 1 1 of patients (2,3). However, postprandial ANDREA SIEBENHOFER, MD THOMAS R. PIEBER, MD blood glucose peaks and excursions are not comparable with nondiabetic sub- jects. Absorption of unmodified insulin from the injection site is a complex pro- cess affected by only partially changeable OBJECTIVE — Both rapid-acting insulin analogs, insulin aspart and lispro, attenuate pran- factors, such as anatomic area, blood dial glucose excursion compared with human soluble insulin. This trial was performed to study flow, injection volume, concentration of the pharmacokinetic and pharmacodynamic profiles of insulin aspart and insulin lispro in type 1 diabetic patients in a direct comparison and to investigate whether the administration of one insulin, and possible local degradation analog results in favorable effects on prandial blood glucose control. process (4–6). Therefore, considerable attention has been devoted to the devel- RESEARCH DESIGN AND METHODS — A total of 24 type 1 diabetic patients (age opment of insulin molecules with accel- 36 Ϯ 8 years, 16 men and 8 women, BMI 24.3 Ϯ 2.6 kg/m2, diabetes duration 17 Ϯ 11 years, erated absorption kinetics (7–9). This Ϯ HbA1c 7.9 0.8%) on intensified insulin therapy were recruited into a single-center, random- more physiological profile of these short- ized, double-blind, two-period, cross-over, glucose clamp trial.
    [Show full text]
  • Ep 2330124 A2
    (19) TZZ ¥¥Z_ T (11) EP 2 330 124 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.06.2011 Bulletin 2011/23 C07K 14/575 (2006.01) (21) Application number: 10012149.0 (22) Date of filing: 11.08.2006 (84) Designated Contracting States: • Lewis, Diana AT BE BG CH CY CZ DE DK EE ES FI FR GB GR San Diego, CA 92121 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Soares, Christopher J. SK TR San Diego, CA 92121 (US) • Ghosh, Soumitra S. (30) Priority: 11.08.2005 US 201664 San Diego, CA 92121 (US) 17.08.2005 US 206903 • D’Souza, Lawrence 12.12.2005 US 301744 San Diego, CA 92121 (US) • Parkes, David G. (62) Document number(s) of the earlier application(s) in San Diego, CA 92121 (US) accordance with Art. 76 EPC: • Mack, Christine M. 06801467.9 / 1 922 336 San Diego, CA 92121 (US) • Forood, Behrouz Bruce (71) Applicant: Amylin Pharmaceuticals Inc. San Diego, CA 92121 (US) San Diego, CA 92121 (US) (74) Representative: Gowshall, Jonathan Vallance et al (72) Inventors: Forrester & Boehmert • Levy, Odile Esther Pettenkoferstrasse 20-22 San Diego, CA 92121 (US) 80336 München (DE) • Hanley, Michael R. San Diego, CA 92121 (US) Remarks: • Jodka, Carolyn M. This application was filed on 30-09-2010 as a San Diego, CA 92121 (US) divisional application to the application mentioned under INID code 62. (54) Hybrid polypeptides with selectable properties (57) The present invention relates generally to novel, tions and disorders include, but are not limited to, hyper- selectable hybrid polypeptides useful as agents for the tension, dyslipidemia, cardiovascular disease, eating treatment and prevention of metabolic diseases and dis- disorders, insulin-resistance, obesity, and diabetes mel- orders which can be alleviated by control plasma glucose litus of any kind, including type 1, type 2, and gestational levels, insulin levels, and/or insulin secretion, such as diabetes.
    [Show full text]